Antiretroviral therapy for pregnant women (Q41378473)

30 September 2017

1 reference

title

Antiretroviral therapy for pregnant women (English)

1 reference

30 September 2017

1 reference

Minkoff H

1

1 reference

PubMed ID

9065202

30 September 2017

Augenbraun M

series ordinal

2

1 reference

PubMed ID

9065202

30 September 2017

language of work or name

English

0 references

publication date

1 February 1997

1 reference

American Journal of Obstetrics and Gynecology

30 September 2017

1 reference

30 September 2017

176

1 reference

30 September 2017

2

1 reference

30 September 2017

478-489

1 reference

Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group

30 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2970519-2

Human Immunodeficiency Virus Infection in Pregnant Women Under Care at AIDS Clinical Trials Centers in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2970519-2

The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2970519-2

A randomized controlled trial of a reduced daily dose of zidovudine in patients with the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2970519-2

The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trials Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2970519-2

Antiretroviral therapy for adult HIV-infected patients. Recommendations from a state-of-the-art conference. National Institute of Allergy and Infectious Diseases State-of-the-Art Panel on Anti-Retroviral Therapy for Adult HIV-Infected Patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2970519-2

A controlled trial of early versus late treatment with zidovudine in symptomatic human immunodeficiency virus infection. Results of the Veterans Affairs Cooperative Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2970519-2

Cardiac structure and function in children with human immunodeficiency virus infection treated with zidovudine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2970519-2

Zidovudine-associated embryonic toxicity in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2970519-2

Effect of zidovudine on preimplantation murine embryos

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2970519-2

A survey of zidovudine use in pregnant women with human immunodeficiency virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2970519-2

The pharmacokinetics and safety of zidovudine in the third trimester of pregnancy for women infected with human immunodeficiency virus and their infants: phase I acquired immunodeficiency syndrome clinical trials group study (protocol 082). Zidovudi

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2970519-2

Pharmacokinetic disposition of zidovudine during pregnancy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2970519-2

Factors predictive of maternal-fetal transmission of HIV-1. Preliminary analysis of zidovudine given during pregnancy and/or delivery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2970519-2

Therapy for human immunodeficiency virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2970519-2

Long-term persistence of zidovudine resistance mutations in plasma isolates of human immunodeficiency virus type 1 of dideoxyinosine-treated patients removed from zidovudine therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2970519-2

Rates and risk factors for adverse events associated with didanosine in the expanded access program

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2970519-2

Didanosine compared with continuation of zidovudine in HIV-infected patients with signs of clinical deterioration while receiving zidovudine. A randomized, double-blind clinical trial. The Bristol-Myers Squibb AI454-010 Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2970519-2

A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. The NIAID AIDS Clinical Trials Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2970519-2

Fetoplacental passage of 2',3'-dideoxyinosine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2970519-2

The transfer of anti-human immunodeficiency virus nucleoside compounds by the term human placenta

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2970519-2

Combination therapy with zidovudine and dideoxycytidine in patients with advanced human immunodeficiency virus infection. A phase I/II study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2970519-2

Developmental toxicity of orally administered 2',3'-dideoxycytidine in mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2970519-2

Effect of six virustatic nucleoside analogues on the development of fetal rat thymus in organ culture

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2970519-2

From the Food and Drug Administration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2970519-2

Genotypic and phenotypic analysis of human immunodeficiency virus type 1 isolates from patients on prolonged stavudine therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2970519-2

Comparative embryonic cytotoxicity of antiretroviral nucleosides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2970519-2

Lamivudine or stavudine in two- and three-drug combinations against human immunodeficiency virus type 1 replication in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2970519-2

A preliminary trial of lamivudine for chronic hepatitis B infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2970519-2

Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. North American HIV Working Party

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2970519-2

Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2970519-2

Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2970519-2

A synthetic HIV-1 protease inhibitor with antiviral activity arrests HIV-like particle maturation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2970519-2

Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2970519-2

A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2970519-2

A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2970519-2

Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group P

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2970519-2

New anti-HIV drugs and treatment strategies buoy AIDS researchers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2970519-2

Combination superior to zidovudine in Delta trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2970519-2

Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2970519-2

Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2970519-2

In vivo resistance to a human immunodeficiency virus type 1 proteinase inhibitor: mutations, kinetics, and frequencies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2970519-2

A comparison of immediate with deferred zidovudine therapy for asymptomatic HIV-infected adults with CD4 cell counts of 500 or more per cubic millimeter. AIDS Clinical Trials Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2970519-2

A controlled trial of zidovudine in primary human immunodeficiency virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2970519-2

Prognosis in HIV-1 infection predicted by the quantity of virus in plasma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2970519-2

HIV viral load markers in clinical practice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2970519-2

Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. International AIDS Society-USA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2970519-2

Maternal plasma human immunodeficiency virus type 1 RNA level: a determinant and projected threshold for mother-to-child transmission

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2970519-2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2970519-2

Selective transmission of human immunodeficiency virus type-1 variants from mothers to infants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2970519-2

Scope of the AIDS epidemic in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2970519-2

What is obstetric ethics?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2897%2970519-2

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0002-9378(97)70519-2

1 reference

30 September 2017

1 reference

PubMed ID

9065202